Dear Readers,
Welcome to this week's Byte.
Today, I want to talk about a company that sits at the very foundation of the AI infrastructure buildout - and yet rarely makes headlines. I've written about the AI infrastructure boom many times in previous bytes. This week, I want to go into the weeds on one of the businesses quietly collecting a toll on all of it.
That company is Synopsys (SNPS).
Synopsys was founded in 1986 and has spent nearly 40 years becoming one of the two dominant providers of the software used to design semiconductors.
What makes Synopsys particularly interesting to me today is its position at the intersection of two powerful forces: the AI-driven explosion in chip complexity, and its expansion into system-level simulation through the Ansys acquisition.
By now, you probably know me well enough to know that I'm always looking for quality compounders that have the potential to become multi-baggers over time.
Synopsys is one company that I believe deserves a closer look.
So, What Does Synopsys Actually Do?
At its core, Synopsys makes Electronic Design Automation software - EDA for short.
Think of it this way: before a chip is manufactured, it is designed twice - once in software, and once in silicon. Synopsys provides the software for the first part: the tools engineers use to draw, test, and simulate a chip down to the tiniest transistor, long before a factory builds anything.
Every smartphone processor, AI accelerator, and car chip is designed using EDA tools, acting as a digital blueprint and virtual testing lab for electronics. Before manufacturing, the software simulates electrical flow and logic to catch short circuits, timing errors, or rule violations early. It then automatically handles the physical layout, figuring out how to pack billions of microscopic transistors into tiny spaces. Once approved, the tool generates the exact files factories need to manufacture the actual hardware.
Through its ~$35 billion acquisition of Ansys, completed last year, Synopsys has expanded beyond chips into simulation software - tools that let engineers test how a product behaves (heat, stress, airflow) on a computer instead of building physical prototypes.
In other words, Synopsys is moving from designing the chip to simulating the entire system around it.
Why AI Is Such a Big Opportunity for Synopsys
This is where the story gets particularly interesting.
AI doesn't make chips simpler. It makes them dramatically more complex - and complexity is Synopsys's growth engine.
Every hyperscaler is now designing its own custom AI chips: Google, Amazon, Meta, and OpenAI are all in this game. Each new chip design is a new blueprint drawn in Synopsys's software. More chip design means more demand for the tools.
There is also a fashionable fear I want to address head-on: if AI can design chips by itself, who needs chip-design software? We have seen this movie before. A few months ago, people argued AI would destroy Microsoft's Office business because companies would need fewer workers. Instead, Microsoft embedded AI directly into its products through Copilot, making the software more valuable and expanding what users could accomplish.
In my view, Synopsys is following a similar path. Rather than being disrupted by AI, it is incorporating AI into its own design tools, helping engineers work faster and tackle increasingly complex chip designs. At the same time, the AI boom is creating more chips that need to be designed in the first place.
The key point is that AI increases the complexity of semiconductor design, and complexity is Synopsys's growth engine. Whether those chips are being developed by Nvidia, Google, Amazon, Meta, OpenAI, or hundreds of smaller companies, they still need sophisticated design tools to get from concept to production.
What Moats Does Synopsys Have?
When I evaluate a company, I don't just want to know whether revenue is growing.
I want to understand why the company can continue to grow and what protects that growth from competitors.
For Synopsys, two important advantages stand out.
1. A Duopoly Market Structure
Synopsys and Cadence together control roughly three-quarters of the EDA market, with Siemens a distant third. When two companies own the blueprints for an entire industry, new competitors face an almost impossible climb: decades of accumulated engineering, customer trust, and tooling they'd have to replicate.
2. Switching Costs and Customer Relationships
Synopsys's software gets woven into years of a customer's chip designs and engineering workflows. If a tool is used to design a processor going into production at massive scale, reliability matters far more than price. Switching tools midstream would mean requalification, retesting, redesign, and real operational risk.
Once a supplier is designed in and has a track record, customers stay. That creates a meaningful barrier - and pricing power.
Now Let's Look at the Numbers
At its Investor Day earlier this month, Synopsys guided next fiscal year's revenue to $11.10–$11.20 billion, above Wall Street's $10.81 billion expectation, with earnings per share of $19.04–$19.12 versus $17.81 expected.
Longer term, management is targeting approximately:
- 15% annual revenue growth through 2030
- Operating margins (profit per dollar of sales) rising from ~44% next year toward ~50% by 2030 - elite software economics
- A $1 billion share buyback, which leaves each remaining share owning a bigger slice of the business
One note on the financials: reported (GAAP) profit margins currently look depressed - around 11% net margin - but that reflects accounting charges from the Ansys acquisition, not the economics of the business. The number I'm watching is the non-GAAP operating margin marching toward 50%.
The balance sheet is conservative, with a debt-to-equity ratio of approximately 0.3 - modest leverage for a business of this quality.
The Investor Day Became the Catalyst
The Investor Day itself was the catalyst that changed the conversation around this stock.
Alongside the better-than-expected guidance, Synopsys announced a multi-year, $1B+ licensing deal with Amazon's AWS and the OpenAI revenue-sharing partnership. These announcements reinforced management's view that AI is becoming an incremental growth driver for the business.
Analysts responded: 22 of 24 now rate the stock a Buy, KeyBanc raised its price target to $605, and one research firm called the presentation "significantly more than the market expected."
The stock did run up roughly 28% to about $510 in early October. However, following last week's market selloff, the stock is now trading at approximately $454.
Forecast and Valuation
Now, let's look at what the numbers could tell us about the stock's potential from here.
A great business can still be a bad investment if you pay too much for it.
The company's own targets imply roughly 15% annual revenue growth with expanding margins, which should translate into even faster earnings growth. I am going to be slightly more conservative and use 12% annual EPS growth for my own scenario.
Starting from next year's guided Non-GAAP EPS (adjusted) of approximately $19.10, that puts EPS at roughly $33.60 in five years.
If the market were willing to assign a P/E multiple of 30 to those earnings - roughly in line with where the stock trades today - that would imply a potential share price of approximately $1,009.
At a price ranging between $454 to $500, it represents roughly a 2x increase in the share price.
Of course, this is not a prediction.
It is simply a valuation exercise based on a set of assumptions.
The stock has traded between approximately $363 and $539 over the past 52 weeks.
If I use the 52-week low of $363 as a downside reference point, my upside-to-downside calculation would be:
($1,009 - $510) / ($510 - $363) = approximately 3.4 : 1
Again, this calculation is only as good as the assumptions behind it.
Another way to look at it: Synopsys trades at roughly 9x next year's sales - what investors call the price-to-sales ratio, or what you pay for each dollar of yearly revenue. That's some discount to its own 5-year average of 12x and well below rival Cadence at roughly 14x. But I want to be honest about what that discount means: Cadence earns its premium with fatter margins and a cleaner record. Synopsys only closes the gap if the Ansys integration delivers and margins march toward 50%. The re-rating is the bet; it is not guaranteed.
And that brings me to the biggest issue with Synopsys today.
Valuation.
After the recent run, the stock trades at a premium multiple of earnings, and the market is beginning to recognize the quality of the business.
That means the company doesn't necessarily have to disappoint for the stock price to decline. If growth expectations moderate or the valuation multiple contracts, the stock could experience a meaningful pullback.
What Could Go Wrong?
Like every investment, Synopsys comes with risks.
Premium valuation: The biggest risk, in my view, is simply paying too much for a great business. A high-growth company can still produce disappointing investment returns if the starting valuation is too high.
Ansys integration: At ~$35 billion, this is the largest acquisition in the company's history. Integrations can slip, promised savings can disappoint, and the deal has left the share count higher. Shareholder lawsuits and an activist-investor settlement add noise on top.
The AI-Replacement narrative: Even though I believe the fear is overblown, it moves the stock - an AI-designed-chip headline caused a real selloff this past summer. Sentiment is a risk whether or not the logic holds.
Geopolitical risk: Export controls restrict selling advanced chip-design tools into China, and the semiconductor cycle itself breathes in booms and busts that affect R&D spending.
My Investment Thesis
So, why does Synopsys interest me?
Because this is more than just an AI story.
It is a duopoly toll booth sitting at the foundation of the AI chip buildout, expanding into the much larger world of system simulation.
AI complexity drives demand for chip-design tools. The Ansys acquisition opens a ~$1.7 trillion product-development market where only about 10% of work is currently simulated virtually. And the business has high switching costs, expanding margins, and a conservative balance sheet.
I have also learned the hard way that waiting for the perfect entry can mean missing a great company entirely. So I bought a starter when the thesis checked out, and I add on weakness rather than chasing strength.
The question isn't whether Synopsys is a good business.
For me, the more important question is:
What price am I willing to pay for this business and its future growth?
At today's valuation, after the recent run, that question becomes especially important.
And that is often where the difference between a great company and a great investment opportunity begins.
With that, I'll rest my case. I hope this Byte has given you a better understanding of Synopsys and, more importantly, how I think about a company while investing.
As always, the thoughts shared in this Byte are meant to help you think more clearly about investing, not to tell you what to buy or sell. Every investor's situation is unique, so please do your own due diligence before making any investment decisions.
And I shall see you next Monday.
Until then…
Invest Smart with Pooja :)